GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Up 556.9% in December

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 90,000 shares, an increase of 556.9% from the December 15th total of 13,700 shares. Currently, 4.6% of the company’s shares are short sold. Based on an average daily volume of 365,300 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Ratings Changes

Several equities research analysts have recently commented on GTBP shares. Roth Mkm initiated coverage on GT Biopharma in a report on Monday, December 2nd. They set a “buy” rating and a $11.00 price objective for the company. Roth Capital raised GT Biopharma to a “strong-buy” rating in a research report on Monday, December 2nd.

GT Biopharma Price Performance

NASDAQ GTBP traded up $0.13 during trading on Tuesday, reaching $2.52. The company’s stock had a trading volume of 114,125 shares, compared to its average volume of 536,828. The firm has a fifty day moving average of $2.85 and a 200 day moving average of $2.57. GT Biopharma has a one year low of $1.72 and a one year high of $10.66.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.